Management

This page includes content on healthcare management, including health system, hospital, department and clinic business management and administration. Areas of focus are on cardiology and radiology department business administration. Subcategories covered in this section include healthcare economics, reimbursement, leadership, mergers and acquisitions, policy and regulations, practice management, quality, staffing, and supply chain.

Thumbnail

Castlight finds wide variation in commodity-type medical services

While the complexity of medicine may never fully allow pure commodity economics in healthcare services, certain services, such as diagnostic imaging and laboratory tests, do lend themselves toward being shopped for as commodities. In theory, this should make such services more sensitive to price pressure. But that is not what San Francisco healthcare technology firm Castlight Health found when it examined four such services: low-back MRI, head CT, lipid panel and preventive primary care visit.

Thumbnail

Hospital mergers and profits come under fire in Massachusetts

Massachusetts, the first state to enact a universal health insurance coverage law, may also be among the first to experience the political upheaval that could come with healthcare reform driven changes.

Thumbnail

Premier analysis finds Medicare tracking of hospital-acquired conditions insufficient

Creating an accurate system for evaluating hospital quality for payments, as well as spotting areas where savings could be achieved and deaths prevented, is becoming increasingly important to health system leaders. However, the current list of hospital-acquired conditions (HACs) that Medicare uses to set payments for hospitals, may be too narrow finds an analysis of discharge codes conducted by the Premier Inc. healthcare alliance.

Thumbnail

Cantor loss changes picture for healthcare lobbying efforts

News media and pundits have largely focused on what House Majority Leader Rep. Eric Cantor’s Virginia Republican primary loss to David Brat means for immigration reform, but Cantor was also heavily involved in drafting the Republican alternative to the Affordable Care Act (ACA).

Thumbnail

CMS: March ICD-10 testing week very successful

The Centers for Medicare & Medicaid Services’ ICD-10 testing week conducted in March proved successful, with the agency accepting 89 percent of the test claims and some regions reporting acceptance rates as high as 99 percent.

Press Ganey Acquires National Database of Nursing Quality Indicators (NDNQI®)

June 10, 2014, Boston, Massachusetts – Press Ganey today announced the acquisition of the National Database of Nursing Quality Indicators (NDNQI®), the leading quality improvement and nurse engagement tool developed by the American Nurses Association (ANA) and managed by The University of Kansas School of Nursing. The acquisition strengthens Press Ganey’s ability to empower nurses and nursing leaders in their mission to reduce patient suffering and improve the patient experience.

Thumbnail

HITPC: Modest growth in EPs and EHs attesting to MU Stage 2

As of the end of May, 447 eligible professionals and eight eligible hospitals have attested to Meaningful Use Stage 2, Elisabeth Myers, policy and outreach lead at the Centers for Medicare & Medicaid Services, told the Health IT Policy Committee during its virtual meeting on June 10.

Banner Health facilities win prestigious stroke award

Thanks to robust IT practices and aggressive use of medications and risk-reduction therapies, six Banner Health facilities in Arizona received the Get With The Guidelines-Stroke Gold-Plus Quality Achievement Award.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.